Clinical trial findings reveal hormone replacement therapy reduces liver and cardiometabolic disease risk in peri-menopausal individuals, suggesting further research is needed.
Treatment of peri-menopausal symptoms with HRT, in patients with pre-existing MASLD, is associated with a lower 5-year risk of major liver and cardiometabolic disease. These findings support early basic science research and should prompt a closer examination through clinical trials.
No takes yet. Share an insight, caveat, or question.
Henney et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: